Private investment firm Hildred Capital Partners plans to acquire a majority stake in pharmaceutical company Crown Laboratories.

Both companies involved in the transaction are based in the US.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Novartis plans to acquire Advanced Accelerator Applications (AAA) for $3.9bn.

Novartis is a pharmaceutical company based in Switzerland, while AAA is a French radiopharmaceutical company.

Neos Therapeutics, Inc. (formerly Neostx Inc.) has rejected PDL BioPharma’s plans to acquire its entire outstanding shares for $10.25 a share.

“Novartis plans to acquire Advanced Accelerator Applications (AAA) for $3.9bn.”

Both pharmaceutical companies involved in the transaction are based in the US.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Alembic Pharmaceuticals has acquired generic drug developer Orit Laboratories.

The acquisition enables the Indian pharmaceutical company to expand its footprint in the US.

US-based biotechnology company Amgen plans to acquire the remaining 50% stake in Kirin-Amgen, a joint venture (JV) between integrated beverage company Kirin Holdings and Amgen.

The JV will pay $780m to Kirin and consequently become a wholly owned subsidiary of Amgen.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact